Drug intelligence / Profile preview

JAN123

Development stage: Unknown
Lead developer: ALT 5 Sigma
Modality: Small Molecules
Administration: Oral

Overview

JAN123 is a novel, patent-pending, extended-release formulation of low-dose naltrexone (LDN) being developed for the treatment of Complex Regional Pain Syndrome (CRPS). Originally developed by Soin Therapeutics and acquired by JanOne in 2022, the drug aims to provide a non-addictive alternative for chronic pain management, addressing the opioid crisis. JAN123 has received Orphan Drug Designation from the FDA for CRPS. The mechanism involves the modulation of glial cells and the antagonism of Toll-like receptor 4 (TLR4), which helps reduce neuroinflammation and central sensitization associated with CRPS.

Other names: low-dose naltrexoneLDN

Targets

KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on JAN123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JAN123.

Explore the full profile